INNOVATIVE CELL-BASED URINALYSIS FOR PATIENT ADHERENCE

描述（由申请人提供）：这项小型企业创新研究（SBIR-Phase II）提案的科学和商业目标是开发基于细胞的检测方法，用于检测体液中具有生物活性的补充和替代医学（CAM）制剂。拟议的项目建立在分子测定的基础上，通过最近的第一阶段资金设计和验证。通过体外生物发光成像系统识别体液中CAM试剂的策略补充了Swaasth Inc开发的另一种药物发现技术，称为遗传表达和测量（GEMTM）。总之，这些基于细胞的CAM代理检测技术将使新技术的发展，在监测客观的措施，遵守研究方案的CAM模式的调查。斯瓦斯特公司具有 成功开发了分子试剂和高通量筛选基础设施， 识别CAM代理。预计GEM系统的可用性将有效利用 第二阶段的资金，以进一步扩大检测各种CAM代理人，并提高 临床环境中CAM模态的微创患者依从性测量。

DESCRIPTION (provided by applicant): The scientific and commercial goal of this small business innovation research (SBIR-Phase II) proposal is to develop cell-based assays for the detection of biologically active complementary and alternative medicine (CAM) agents in body fluids. The proposed project builds on the foundation of a molecular assay designed and validated through a recent Phase I funding. The strategy of identifying CAM agents in body fluids by an in vitro bio-luminescence imaging system complements another drug-discovery technology developed at Swaasth Inc, referred to as Genetic Expression and Measurement (GEMTM). Together, these cell-based CAM agent detection technologies will enable the development of novel technologies in monitoring objective measures of adherence to study-protocol in the investigations of CAM modalities. Swaasth Inc. has successfully developed molecular reagents and high throughput-screening infrastructure required to identify CAM agents. It is anticipated that the availability of GEM system will make effective use of the Phase II funding to further expand the detection of a variety of CAM agents and enhance minimally invasive patient adherence measurements for CAM modalities in clinical settings.